The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
Open accessAbstract
BACKGROUND: Thymoquinone (TQ) is a compound extracted from Black Caraway seeds of Nigella Sativa and is active against various cancers. Cisplatin (CDDP) is the most active chemotherapeutic agent in Lung Cancer. Here we report activity of TQ against non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cell lines alone and in combination with Cisplatin (CDDP). METHODS: For proliferation MTT assay, cell viability trypan blue assay and for apoptosis Annexin-V FITC assay were used in NCI-H460 and NCI-H146 cell lines. Inhibition of invasion by TQ was assessed using Matrigel assay and its affect on release of various cytokines was determined using RayBio Human Cytokine detection kit. Mouse xenograft model using NCI-H460 was used to determine in vivo activity of TQ and CDDP. Inhibition of LPS induced NF-kappaB expression by TQ was determined using transgenic mice expressing a luciferase reporter. RESULTS: TQ was able to inhibit cell proliferation, reduce cell viability and induce apoptosis. TQ at 100 microM and CDDP at 5 muM inhibited cell proliferation by nearly 90% and the combination showed synergism. TQ was able to induced apoptosis in both NCI-H460 and NCI-H146 cell lines. TQ also appears to affect the extracellular environment inhibiting invasion and reducing the production of two cytokines ENA-78 and Gro-alpha which are involved in neo-angiogenesis. Using a mouse xenograft model we were able to demonstrate that combination of TQ and CDDP was well tolerated and significantly reduced tumor volume and tumor weight without additional toxicity to the mice. In the combination arms (TQ5 mg/kg/Cis 2.5 mg/kg) tumor volume was reduced by 59% and (TQ20 mg/kg/Cis 2.5 mg/kg) by 79% as compared to control which is consistent with in vitro data. TQ down regulated NF-kappaB expression which may explain its various cellular activities and this activity may prove useful in overcoming CDDP resistance from over expression of NF-kappaB. CONCLUSIONS: Thus TQ and CDDP appear to be an active therapeutic combination in lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 2×
“In the combination groups [7,8] diffuse tubular damage and acute tubular necrosis (ATN) was noted in 40-80% of samples.”
BackgroundCellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27348 · Cited by 1,222
Arenberg, D. A., Keane, M. P., DiGiovine, B., Kunkel, S. L., Morris, S. B., Xue, Y. Y., Burdick, M. D., Glass, M. C., Iannettoni, M. D., & Strieter, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3145 · Cited by 259
Cited by
Thymoquinone: Potential cure for inflammatory disorders and cancer
Woo, C. C., Kumar, A. P., Sethi, G., & Tan, K. H. B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.09.029 · Cited by 541
Thymoquinone and its therapeutic potentials
Darakhshan, S., Bidmeshki Pour, A., Hosseinzadeh Colagar, A., & Sisakhtnezhad, S. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.011 · Cited by 507
Spices for Prevention and Treatment of Cancers
Zheng, J., Zhou, Y., Li, Y., Xu, D.-P., Li, S., & Li, H.-B. (2016) · Nutrients · doi:10.3390/nu8080495 · Cited by 329
Anticancer Activity of Nigella sativa (Black Seed) — A Review
Randhawa, M. A., & Alghamdi, M. S. (2011) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x1100941x · Cited by 272
Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review
Kamran, S., Sinniah, A., Abdulghani, M. A. M., & Alshawsh, M. A. (2022) · Cancers · doi:10.3390/cancers14051100 · Cited by 259
Metadata
- Authors
- Jafri, S. H., Glass, J., Shi, R., Zhang, S., Prince, M., & Kleiner-Hancock, H.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2010-07-01
- Volume
- 29
- Issue
- 1
- Pages
- 87-87
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W2157443457
- Cited by
- 238
- References
- 6
- FWCI
- 29.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. https://app.cochat.ai/papers/10.1186/1756-9966-29-87
- The paper
- Jafri, S. H., Glass, J., Shi, R., Zhang, S., Prince, M., & Kleiner-Hancock, H. (2010). Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/1756-9966-29-87
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.